Clinical trials: Breast Cancer/ Metastatic Breast Cancer
Invasive Breast Cancer, Metastatic Breast Cancer
Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC
This research study is evaluating the safety and effectiveness of Sacituzumab Govitecan with or without Pembrolizumab in metastatic HR+/HER2- breast cancer.
- Conditions
- Invasive Breast Cancer, Metastatic Breast Cancer, HR-Positive Breast Cancer, HER2-negative Breast Cancer
- Trial name
- NCT04448886
- Testing
- Pembrolizumab, Sacituzumab Govitecan
- Where
- 8 sites in United States
- Volunteers
- 110 people
- Sponsor
- Ana C Garrido-Castro, MD
Stage IV Prostate Cancer, Stage IV Colon Cancer
Dibenzyl Trisulphide (GUINEAHEN WEED) for Stage IV Cancer
This study is being done to find the effect of Dibenzyl Trisulphide (active ingredient in Guinea Hen Weed in combination in patients with stage four cancer of the breast, prostate, cervix and colon.
- Conditions
- Stage IV Prostate Cancer, Stage IV Colon Cancer, Stage IV Breast Cancer, Stage IV Cancer of the Cervix
- Trial name
- NCT04113096
- Testing
- Dibenzyl trisulphide capsules
- Where
- Jamaica
- Volunteers
- 104 people
- Sponsor
- The University of The West Indies
Locally Advanced Cancer, Metastatic Cancer
Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy
The purpose of this study is to determine if the radiotracer, [68Ga]Ga-ABY-025, used for PET imaging can help us better identify and visualize lesions or tumors, in patients who are receiving standard of care therapy HER2+…
- Conditions
- Locally Advanced Cancer, Metastatic Cancer, HER2, HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT06828588
- Testing
- [68Ga]Ga-ABY-025
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Breast Neoplasms, Secondary
Pilot Imaging Study With 89Zr-Trastuzumab in HER2-positive Metastatic Breast Cancer Patients
Evaluation of the diagnostic potential of HER2 imaging using zirconium 89 labelled trastuzumab.
- Conditions
- Breast Neoplasms, Secondary, HER2 Positive Carcinoma of Breast
- Trial name
- IJBMNZrT003 (NCT01420146)
- Testing
- Zr89-trastuzumab
- Where
- Belgium
- Volunteers
- 20 people
- Sponsor
- Jules Bordet Institute
Neoplasm, Breast, Neoadjuvant Chemotherapy
To Accurately Assess Lymph Node Response to NACT by Wire Localization of Clip-marked Lymph Nodes
The investigator developed this protocol to accurately assess lymph node response to neoadjuvant chemotherapy in clinical stage N1 (cN1) breast cancer patients.
- Conditions
- Neoplasm, Breast, Neoadjuvant Chemotherapy, Lymph Node Metastases, Response
- Trial name
- NCT03715686
- Testing
- wire localization
- Where
- China
- Volunteers
- 230 people
- Sponsor
- Peking University
Breast Cancer
Correlation of Molecular Markers With Response to Therapy and Breast Cancer Behavior
RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01000883
- Testing
- biologic sample preservation procedure, laboratory biomarker analysis, biopsy
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Breast Cancer, Colorectal Cancer
Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer
- Trial name
- NCT00667641
- Testing
- bortezomib, paclitaxel
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Breast Cancer, Cervical Cancer
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive
Background: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy for treating patients with cancer that involves taking white blood cells from the patient, growing them in the laboratory in…
- Conditions
- Breast Cancer, Cervical Cancer, Renal Cancer, Melanoma
- Trial name
- NCT02153905
- Testing
- Aldesleukin, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Breast Neoplasms, Treatment
Classified Treatment Strategy for De-novo Metastatic Breast Cancer After Systemic Adjuvant Therapy
For patients with de novo stage IV breast cancer, the current debate is whether local surgery can improve the survival of patients.
- Conditions
- Breast Neoplasms, Treatment, Metastatic Breast Cancer, Survival
- Trial name
- CS (NCT05285332)
- Testing
- surgical treatment 1, surgical treatment 2, Systemic therapy
- Volunteers
- 362 people
- Sponsor
- Changhai Hospital
Metastatic Breast Cancer
Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP
2X-121 is a small molecule targeted inhibitor of Poly ADP ribose polymerase (PARP), a key enzyme involved in DNA damage repair in cancer cells.
- Trial name
- NCT03562832
- Testing
- PARP inhibitor 2X-121
- Where
- 2 sites in Denmark
- Volunteers
- 20 people
- Sponsor
- Allarity Therapeutics
Breast Cancer
Treatment After Progression of Fulvestrant Among Metastatic Breast Cancer Patients
What Comes After Fulvestrant? A Real World Multicenter Retrospective Study-Treatment After Progression of Fulvestrant Among Metastatic Breast Cancer Patients in China.
- Trial name
- NCT03541863
- Where
- China
- Volunteers
- 131 people
- Sponsor
- Fudan University
Breast Cancer
MRI in Predicting Tumor Reponse After Radiofrequency Ablation in Women With Invasive Breast Cancer
RATIONALE: Radiofrequency ablation uses a high-frequency, electric current to kill tumor cells. Diagnostic procedures, such as magnetic resonance imaging (MRI), may help in learning how well radiofrequency ablation works to kill…
- Trial name
- NCT00373152
- Testing
- Lumpectomy, dynamic contrast-enhanced magnetic resonance imaging, radiofrequency ablation
- Sponsor
- Masonic Cancer Center, University of Minnesota
Breast Cancer, Lymph Node Metastasis
Axillary LNs Evalution in Breast Cancer by Multimodal Us
The present study is designed to evaluate the role of simultaneous multi-modal sonographic tools-Ultrasound (US), Color Doppler Ultrasound (CDU), and Ultrasound Elastography (UE)-in determining the nature (benign or malignant) of…
- Trial name
- NCT06695052
- Testing
- multi modal Us
- Volunteers
- 30 people
- Sponsor
- Assiut University
Liver Cancer (Locally Advanced or Metastatic), Lung Cancer (NSCLC)
A Study of SH009 Injection in Patients With Advanced Solid Tumors.
Evaluate the efficacy and safety of SH009 injection therapy for patients with advanced solid tumors
- Conditions
- Liver Cancer (Locally Advanced or Metastatic), Lung Cancer (NSCLC), Head and Neck Cancer Squamous Cell Carcinoma, Breast Cancer (Locally Advanced or Metastatic)
- Trial name
- NCT07390838
- Testing
- SH009
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
Metastatic Breast Cancer
IMP321 Plus First-line Paclitaxel in Metastatic Breast Carcinoma
Open label, non-randomized, fixed dose-escalation phase I study, performed in ambulatory setting in patients receiving as a first line chemotherapy for metastatic breast carcinoma the standard 6 cycles of weekly paclitaxel (80…
- Trial name
- NCT00349934
- Testing
- IMP321
- Where
- 3 sites in France
- Volunteers
- 33 people
- Sponsor
- Immutep S.A.S.
Breast Cancer
A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer
This is a phase I, open-label study of D-0502 single agent and D-0502 in combination with standard dose of palbociclib to assess the safety and tolerability, identify an MTD, and/or RP2D, evaluate the PK properties and evaluate…
- Trial name
- NCT03471663
- Testing
- D-0502, palbociclib
- Where
- 15 sites in United States, China
- Volunteers
- 200 people
- Sponsor
- InventisBio Co., Ltd
Metastatic HER2-Positive Breast Cancer
Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy
The purpose of this study is to see if a combination of drugs can help to treat breast cancer. This is a Phase II study which will test whether this combination of drugs is effective and will provide further information on side…
- Trial name
- NCT02252887
- Testing
- Gemcitabine, Trastuzumab, Pertuzumab
- Where
- 5 sites in United States
- Volunteers
- 45 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer
The Impact of Obesity and Obesity Treatments on Breast Cancer
The goal of this clinical research study is to find the highest tolerable dose of Avandamet that can be given in combination with exemestane to patients who are obese and postmenopausal with hormone-receptive-positive breast…
- Trial name
- NCT00933309
- Testing
- Exemestane, Avandamet
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- M.D. Anderson Cancer Center
HR+ Breast Cancer, Triple Negative Breast Cancer (TNBC)
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
The goal of this open-label dose escalation and expansion study is to evaluate the safety and tolerability of NKT5097 in adults with advanced/metastatic tumors (emphasis on breast cancer and solid tumors with CCNE1…
- Conditions
- HR+ Breast Cancer, Triple Negative Breast Cancer (TNBC), CCNE1 Amplified Advanced Solid Tumors, HR+ HER2- Breast Cancer
- Trial name
- NCT07029399
- Testing
- NKT5097 CDK2/CDK4 dual degrader, Fulvestrant, Letrozole
- Where
- 18 sites in United States
- Volunteers
- 361 people
- Sponsor
- NiKang Therapeutics, Inc.
Breast Neoplasm, Metastatic Breast Cancer
[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer
In this study positron emission tomography (PET/CT) imaging will be used to evaluate proliferative activity in sites of metastatic disease using the investigational radiotracer [18F]fluorothymidine (FLT).
- Conditions
- Breast Neoplasm, Metastatic Breast Cancer, Rb+ Breast Cancer
- Trial name
- NCT02608216
- Testing
- [18F]FLT, PET/CT, ribociclib
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Pennsylvania
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.